http://www.arteaus.com

Sponsor

Jean-Fran├žois Formela

Cambridge, MA — 

In December 2013 Eli Lilly and Company (NYSE:LLY) acquired all development rights for Arteaus Therapeutics' calcitonin gene-related peptide (CGRP) antibody upon the completion of a Phase 2a clinical trial for the prevention of frequent, recurrent migraine headaches.